Stem cell transplantation for mantle cell lymphoma: Should it ever be used outside clinical trials?

Bone Marrow Transplantation

Volumn 28, Issue 9, 2001, Pages 813-820

  Sweetenham, J W ^a  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

Allogeneic; Autologous; Mantle cell lymphoma; Stem cell transplantation

Indexed keywords

ANTHRACYCLINE DERIVATIVE; CARMUSTINE; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; INTERFERON; MELPHALAN; METHOTREXATE; MONOCLONAL ANTIBODY; PREDNISONE; RITUXIMAB; VINCRISTINE;

ADULT; AGED; CANCER PATIENT; CANCER REGISTRY; CANCER SURVIVAL; CLINICAL TRIAL; DATA BASE; DRUG MEGADOSE; FEMALE; HUMAN; HUMAN CELL; MALE; MANTLE CELL LYMPHOMA; METHODOLOGY; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; PUBLICATION; RANDOMIZATION; SALVAGE THERAPY; SHORT SURVEY; STANDARDIZATION; STEM CELL TRANSPLANTATION; SURVIVAL RATE; TREATMENT OUTCOME; TREATMENT PLANNING; WHOLE BODY RADIATION;

ACTUARIAL ANALYSIS; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE MARROW PURGING; CLINICAL TRIALS; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LYMPHOMA, MANTLE-CELL; MALE; MIDDLE AGED; PROGNOSIS; PROSPECTIVE STUDIES; RANDOMIZED CONTROLLED TRIALS; REGISTRIES; REMISSION INDUCTION; SALVAGE THERAPY; SURVIVAL ANALYSIS; SURVIVAL RATE; TRANSPLANTATION, AUTOLOGOUS; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 0035196897     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1703255     Document Type: Short Survey

References (56)

1. The role of high-dose therapy and autologous hematopoietic stem cell transplantation for mantle cell lymphoma
2. Myeloablative therapy with blood stem cell transplantation is effective in mantle cell lymphoma
3. Sequential high-dose therapy and autologous stem cell transplantation for treatment of mantle cell lymphoma
4. Intensive therapy with peripheral stem cell transplantation in 16 patients with mantle cell lymphoma
5. Long-term disease-free survival of patients with advanced mantle-cell lymphoma following high-dose chemotherapy
6. High-dose chemotherapy with hematopoietic stem cell transplantation in patients with mantle cell or diffuse centrocytic non-Hodgkin's lymphomas: A single center experience on 18 patients
7. High-dose therapy with stem cell transplantation for mantle cell lymphoma: Results and prognostic factors, a single center experience
8. High-dose chemoradiotherapy and anti-B-cell monoclonal antibody-purged autologous bone marrow transplantation in mantle cell lymphoma: No evidence for long-term remission
9. Hyper-CVAD and high-dose methotrexate/cytarabine followed by stem cell transplantation: An active regimen for aggressive mantle cell lymphoma
10. Autologous hematopoietic stem cell transplantation for mantle cell lymphoma
11. Efficacy of autologous stem cell transplantation in mantle cell lymphoma: A 3 year follow up study
12. Clinical and molecular remission after allogeneic blood cell transplantation in a patient with mantle cell lymphoma
13. Allogeneic bone marrow transplantation for refractory mantle cell lymphoma
14. Patients with mantle cell lymphoma relapsing after autologous stem cell transplantation may be rescued by allogeneic transplantation
15. Allogeneic hematopoietic transplantation for mantle cell lymphoma: Molecular remissions and evidence of graft-versus-malignancy
16. A revised European-American classification of lymphoid neoplasms: A proposal from the International Lymphoma Study Group
17. The World Health Organization Classification of Diseases of the Hematopoietic and Lymphoid Systems
18. European Lymphoma Task Force (ELTF): Report of the workshop on mantle cell lymphoma (MCL)
19. A clinical analysis of two indolent lymphoma entities: Mantle cell lymphoma and marginal zone lymphoma (including the mucosa-associated lymphoid tissue and monocytoid B-cell subcategories): A Southwest Oncology Group study
20. Efficacy of four different regimens in 64 mantle-cell lymphoma cases: Clinicopathologic comparison with 498 other non-Hodgkin's lymphoma subtypes
21. Mantle cell lymphoma: Natural history defined in a serially biopsied population over a 20-year period
22. Mantle-cell lymphoma: A population-based study
23. Patterns of survival in mantle cell lymphoma
24. Mantle cell lymphoma - An entity comes of age
25. Mantle cell lymphoma: Correlation of clinical outcome and biologic features with three histologic variants
26. CNS involvement in mantle cell lymphoma
27. Mantle cell lymphoma: A clinicopathologic study of 80 cases
28. Mantle cell lymphoma: Clinical features, treatment and prognosis of 94 patients
29. Mantle cell lymphoma. Presenting features, response to therapy and prognostic factors
30. Mantle cell lymphoma. A clinicopathologic study of 68 cases from the Nebraska Lymphoma Study Group
31. The clinical outcome of 65 cases of mantle cell lymphoma initially treated with non-intensive therapy by the British National Lymphoma Investigation Group
32. European phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle cell lymphoma and previously treated mantle cell lymphoma, immunocytoma and small B-cell lymphocytic lymphoma
33. Treatment of mantle cell lymphoma with rituximab (chimeric monoclonal anti-CD20 antibody): Analysis of factors associated with response
34. Rituxan/CHOP induction therapy in newly diagnosed patients with mantle cell lymphoma
35. P53 gene mutations and protein overexpression are associated with aggressive variants of mantle cell lymphomas
36. P53 mutations in mantle cell lymphoma are associated with variant cytology and predict a poor prognosis
37. Significance of cyclin D1 overexpression for the diagnosis of mantle cell lymphoma: A clinicopathologic comparison of cyclin D1-positive and cyclin D1-negative MCL-like B-cell lymphoma
38. The International Non-Hodgkin's Lymphoma Prognostic Factors Project: A predictive model for aggressive non-Hodgkin's lymphoma
39. New approach to classifying non-Hodgkin's lymphomas: Clinical features of the major histologic subtypes
40. Does transplantation improve outcome in mantle cell lymphoma (MCL)? A study from the EBMT
41. High dose therapy and autologous hematopoietic cell transplantation for mantle cell lymphoma: The Stanford/City of Hope experience
42. A clinical evaluation of the International Lymphoma Study Group
43. Preliminary report of rituximab with intensive chemotherapy for untreated aggressive mantle cell lymphoma (MCL)
44. Peripheral blood stem cell contamination in mantle cell non-Hodgkin lymphoma: The case for purging?
45. Failure of immunologic purging in mantle cell lymphoma assessed by polymerase chain reaction detection of minimal residual disease
46. Immunotherapy of follicular lymphoma with rituximab (chimeric anti-CD20 monoclonal antibody): A UK phase II trial with monitoring of molecular response
47. Successful in vivo purging of CD34-containing peripheral blood harvests in mantle cell and indolent lymphoma: Evidence foe a role of both chemotherapy and rituximab infusion
48. Management of lymphoma recurrence after allogeneic transplantation: The relevance of graft-versus-lymphoma effect
49. Graft-versus-leukemia after allogeneic bone marrow transplantation for chronic lymphocytic leukemia
50. Transplant-lite: Induction of graft-versus-malignancy using fludarabine based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies
51. High-dose chemotherapy with allogeneic or autologous stem cell transplantation for relapsed mantle cell lymphoma: The Seattle experience
52. Treatment of resistant mantle cell lymphoma with allogeneic bone marrow transplantation
53. Autologous and allogeneic stem-cell transplantation for poor-risk mantle cell lymphoma: The City of Hope experience
54. Successful allogeneic stem-cell transplantation with prophylactic stepwise G-CSF primed DLIs for relapse after autologous transplantation in mantle cell lymphoma: A case report and literature review on the in MCL
55. A phase I/II trial of iodine-131-tositumomab (anti-CD20), etoposide, cyclophosphamide, and autologous stem cell transplantation for relapsed B-cell lymphomas
56. DNA vaccines with single-chain Fv fused to fragment C of tetanus toxin induce protective immunity against lymphoma and myeloma